Uncertainty Surrounds Genomic (GHDX), Goldman Starts at Neutral

Article Stock Quotes (1) Comments (0)

Goldman Sachs initiates coverage on Genomic Health Inc. (NASDAQ: GHDX) with a Neutral rating and a price target of $36.00.

Goldman believes Genomic has growth potential, but it is offset by underappreciated market development costs and mounting competition and an uncertain regulatory environment.

"Our proprietary analysis of GHDX’s new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street.," said analyst Isaac Ro.

For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.

Shares of Genomic Health Inc. closed at $33.77 yesterday, with a 52 week range of $20.11-$37.44.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
• Needham & Company Lifts Numbers on 3D Systems (DDD) on Offering, RDPG Deal
• BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?